JLA Archive Login Register My Manuscripts Contact
Instruction for Authors

Go to Instructions for Authors (Kor)

Amended January, 2014
Amended June, 2016

Journal of Lipid and Atherosclerosis (JLA), an open access and peer-reviewed journal, is an official journal of the Korean Society of Lipidology and Atherosclerosis. The JLA is published 2 times a year (June 30 and December 31), and abbreviated title is 'J Lipid Atheroscler'.

The aims of JLA are to publish clinical and basic science on all aspects of lipid and atherosclerosis, thereby sharing scientific information with all other scientific societies. The ultimate goal of JLA is to contribute in the prevention of diseases associated with lipid and atherosclerosis.

The JLA is open to all scientists, who are interested in the areas associated with lipid and atherosclerosis. The JLA publishes articles about education, information, and scientific research on lipid and atherosclerosis related diseases. The JLA publishes original articles, case reports, reviews, and editorials either in Korean or in English.

The JLA is published both in-print and online, and includes key words indexing with Medical Subject Heading (MeSH) terms. Full text is freely available on the official website (http://www.e-jla.org or http://www.lipid.or.kr).

Journal of Lipid and Atherosclerosis is indexed/tracked/covered by KoreaMed, KoreaMed Synapse, KoMCI, CrossRef and Google Scholar.

Manuscript Submission

Journal of Lipid and Atherosclerosis has an online submission and peer review system. Manuscripts must be submitted electronically at http://submit.e-jla.org/, and it also can be accessed through the Society’s website at http://www.lipid.or.kr. Manuscripts should be submitted along with the author’s checklist which is available online.


Journal of Lipid and Atherosclerosis Editorial Office
Room 1706, Taeyeong Desiang 320,
Dongmak-ro, Mapo-gu,
Seoul 04157, Korea
Tel: +82-2-3272-5330
Fax: +82-2-3272-5331

Editorial and Peer Review Process

Manuscripts are examined by the editorial board and re-evaluated by two expert reviewers assigned by the board. Another reviewer can be assigned if needed. Reviewers may request an additional review during the peer review process, and it usually will be accepted. An initial decision will normally be made within 4 weeks of receiving manuscript, and the reviewers' comments are sent to the corresponding author via e-mail. If any corrections have been made, corresponding author must resubmit the revised manuscripts through the E-Submission System. The corresponding author must indicate item by item the alterations that have been made in response to the referees' comments.

Research and Publication Ethics

Copyright: Upon publication of the articles, all the copyrights are transferred to the Korean Society of Lipidology and Atherosclerosis. Articles are accepted on the understanding that no substantial part other than the abstract has been or will be published elsewhere. A copyright transfer form should be submitted to the editorial office by faxing a copy to +82-2-3275-5331, by regular mail, or by emailing the scanned copyright transfer form at the time of acceptance. It is identical to the Creative Commons Attribution Noncommercial License at http://creativecommons.org/licenses/by-nc/3.0/.

Duplicate Publication: A submitted manuscript must be an original paper not previously published or under consideration for publication in other journals. Articles already published in the JLA or another journal will be rejected. If the manuscript contains similar work that has already been published in the JLA or another journal, the author should submit a copy of such material along with the manuscript. The Editorial Committee of the JLA will discuss over the matter of duplicate publication of the submitted manuscript and will decide to accept it or not. Also, the author cannot submit an article published in the JLA to another journal without permission.

Ethical Considerations: All of the manuscripts should be prepared in strict observation of research and publication ethics guidelines and recommendations by the Korean Association of Medical Journal Editors ("Good Publication Practice Guidelines for Medical Journals" http://kamje.or.kr/intro.php?body=publishing_ethics), the International Committee of Medical Journal Editors (http://www.icmje.org/), and the Committee on Publication Ethics (http://publicationethics.org/resources/guidelines). In case of suspected misconduct such as fabrication, falsification or duplication, each ethical issue is followed by recommended actions as advised by COPE guidelines and flowcharts.

Any study including human subjects or human data must be reviewed and approved by a responsible institutional review board (IRB). Please refer to the principles embodied in the Declaration of Helsinki (http://www.wma.net/en/30publications/10policies/b3/index.html) for all investigations involving human materials. Animal experiments also should be reviewed and approved by an appropriate committee (Institutional Animal Care and Use Committee) for the care and use of animals. Also studies with pathogens requiring a high degree of biosafety should pass review of a relevant committee (Institutional Biosafety Committee). The editor of the JLA may request submission of copies of informed consents from human subjects in clinical studies or IRB approval documents.

Authorship: The ICMJE recommends that authorship be based on the following 4 criteria: 1) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND 2) Drafting the work or revising it critically for important intellectual content; AND 3) Final approval of the version to be published; AND 4) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Those who do not meet all four criteria should be acknowledged. The corresponding author must take the responsibility for the integrity of the work as a whole, and must organize and manage the authors. The JLA usually does not allow multiple corresponding or first authors for one article. In such case, it should follow the decision of the Editorial Committee.

Conflict of Interest: At the time of manuscript submission, the JLA requires that corresponding author inform the Editor of the authors' potential conflicts of interest possibly influencing their interpretation of data. A conflict of interest may exist when an author (or the author's institution or employer) has financial support from pharmaceutical or commercial companies or political pressures from interest groups or personal relationships that could influence (or bias) the author's decisions, work, or manuscript. All sources of funding for a study should be stated explicitly.

Journal Categories

The JLA accepts and publishes original articles, case reports, review articles, and editorials.

Manuscript Preparation and Format

The manuscript should be prepared according to "Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations)" (http://www.icmje.org/). In addition to the ICMJE Recommendations, a number of reporting guidelines have been developed by groups of experts to facilitate reporting of research studies or clinical trials (http://www.equator-network.org/library/).

(1) All materials must be written in proper and clear Korean or English using Microsoft Word or Hangul Office word processing software. The manuscript must be typed double-spaced with 2.5 centimeter (1 inch) wide margins on each side of A4 (210 mm * 297 mm), with a font size of 10 point. Each page of the paper must be numbered from the cover.

(2) The manuscript of Original Articles should be arranged as the following sequence: 1) Title Page, 2) Abstract and Key Words, 3) Introduction, 4) Materials and Methods, 5) Results, 6) Discussion, 7) References, 8) Tables, 9) Figures, and 10) Figure Legends. The manuscript should not include author names or affiliations, or any other identifying information in any part other than the Title Page.

1) Title Page: The title page should contain the title of an article, full names of authors, institutional affiliation(s), and running head.

① Title: The title should provide a distilled description of the complete article and should include all information that will make electronic retrieval of the article. The title should not be too short to lack important information, such as study design which is particularly important in identifying randomized, controlled trials.

② Authors: Do not include academic degree after the author name. If several authors and institutions are listed, it should be clearly indicated with which department and institution each author is affiliated by using superscript numbers in sequence.

③ Running Head: Running titles are not usually required. In case of a long title, it should be around 50 characters including letters and spaces on the title page.

④ Information concerning source(s) of support including grants, equipment, drugs, and/or other support that facilitated conduct of the work should be described in the title page.

⑤ An address for correspondence including the name of corresponding author, address, telephone and fax numbers, and email address should be given correctly.

2) Abstract and Key Words: Do not cite references in the abstract. English Abstract should be included even in the Original Articles written in Korean. Be concise (250 words maximum). Use the following headings; Objective, Methods, Results, and Conclusion. Conclusion should include succinct statement of data interpretation, not the reiteration of data summary. Limit use of acronyms and abbreviations. Define acronym or abbreviation at its first use in parentheses. Key words (5 words maximum) should be used from the Medical Subject Headings (MeSH) list of Index Medicus (http://www.nlm.nih.gov/mesh), only first letter be capitalized. If suitable MeSH terms are not available for recently introduced terms, present terms may be used.

3) Introduction: The background and the purpose of the study should be clearly provided, and general information which is not directly related with the study should be excluded. Study result or conclusion should not be described in the introduction.

4) Materials and Methods: The explanation of the experimental methods should be concise and sufficient for repetition by other qualified investigators. Studies in humans must indicate that an institutional review committee approved each study and that the subjects gave informed consent. When reporting the use of reagents or machine, indicate the name of company, city, state, country of the used. Method of statistical analyses and the criteria for determining significance levels should be described.

5) Results: The results should be logically described in detail without giving meaning. Tables, figures, or photos should be used only when necessary without repeating all the data in the text. And their exact location should be displayed properly in the article. The use of the International Standardized (SI) units is encouraged, and the p-value for confidence level should be used in lowercase.

6) Discussion: Discussion should be focused on the interpretation related to the results of the study, while repetition of the contents in the introduction and the results should be avoided. Interpreting the new and important aspects of the study, the results of other related studies should be logically presented, and the implications of novel findings should be emphasized. The significance and limitations of the study should be described, allowable range of the contents of the study results and the goals of the study should be related, and the impact on future research should be described. Conclusion should be expressed in the end of the Discussion without a separate section.

7) The Acknowledgment can be placed after the Discussion if needed, which recognizes all sources of support for research and substantive contributions of individuals. 8) References: Citation of references in the text should be made by giving consecutive number as superscript after comma or period. They should be listed in the order of citation in the text with consecutive numbers in this separate section

Ex) ~ is reported.1,3

Accuracy of reference data is the responsibility of the author. Names of journals should be abbreviated in the style used in Index Medicus, National Library of Medicine (NLM). The description of the journal reference follows the below description.

① Journal Articles: The general format for a reference to a journal article; Authors, Article Title, Journal Title, Date of Publication, Volume, Issue, and Location (Pagination). Enter surname (family or last name) first for each author. Convert given (first) names and middle names to initials, for a maximum of two initials following each surname. List all authors if six or fewer, otherwise list first six and add the "et al.".

Ex) Burstein M, Sholnick HR, Morfin R. Rapid method for isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 1970;11:583-595.

② Books: The general format for a reference to a book; Authors, Title, Edition, Secondary Author, Place of Publication, Publisher, Date of Publication, and Pagination. Ex) Ringsven MK, Bond D. Gerontology and leadership skills for nurses. 2nd ed. Albany (NY) : Delmar Publishers; 1996.

③ Contributions to Books: The general format for a reference to a contribution to a book; Authors of Contribution, Title of Contribution, Connective Phrase, Editor(s) of Book, Title of Book, Place of Publication, Publisher, Date of Publication, and Location of Contribution.

Ex) Phillips SJ, Whisnant JP. Hypertension and stroke. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis, and management. 2nd ed. New York: Raven Press; 1995. p.465-478.

④ Journal Articles on the Internet: The general format for a reference to an article from a journal published on the Internet; Authors, Article Title, Journal Title, Type of Medium, Date of Publication, Date of Citation, Volume Number, Issue Number, Location, and Availability.


⑤ Abstracts or Letters can be cited with the addition of "(Abstract)" or "(Letter)" at the end of the general format for a reference to journal article. Ex) Sweeney RJ, Gill RM, Reid PR. Increased action potential prolongation by low voltage biphasic versus monophasic field stimulation. J Am Coll Cardiol 1995;86A. (Abstract)

⑥ Otherwise it follows the Citing Medicine: The NLM Style Guide for Authors, Editors, and Publishers [Internet]. 2nd edition. Available from: http://www.ncbi.nlm.nih.gov/books/NBK7282/.

9) Tables: Begin each table on a separate page. The table number should be Arabic in the order of its citation in the text, followed by a period and a brief title. Supply a brief heading for each column. Do not use vertical lines between columns. Use horizontal lines above and below the column headings and at the bottom of the table only. Abbreviations used in the table must be defined in a footnote to the table using semicolon (;) without symbols. Indicate footnotes in this order: *, †, ‡, §, ||, ¶, **, ††, ‡‡, §§, ||||, ¶¶

10) Photo or Figure: Figures are to be formatted to GIF, TIFF, EPS, and JPG files with high resolution (minimum 300 dpi for color figures and 600 dpi for black and white images such as radiographs). Photos of pathologic findings (Ex: H&E staining) should be submitted in color, and high quality printed version may be requested in special occasions.

11) Photo or Figure Legends: Legends should be typed double-spaced on pages separate from the text. All symbols used (arrows, circles, etc.) must be explained.

12) Supplemental Materials: Supplemental materials will be published in the e-journal only. They may consist of 1) Information that cannot be printed, such as animations, video clips, and sound recordings, 2) Information that can be presented more conveniently in electronic form and 3) Large original data, e.g. additional tables, illustrations, etc.

(3) Only clinically important and very rare cases are published. A Case Report should comprise Title page, Abstract and Key Words, Introduction, Case Report, Discussion, and References (not more than 20).

1) Title page: Title page follows the instruction in Original Articles.

2) Abstract and Key Words: The abstract should not exceed 200 words, and must be written as one unstructured paragraph in English. Key Words should not exceed 5 words.

3) Introduction: Reasons for reporting a case should be stated in a clear and cohesive manner.

4) Case report: This section should include relevant elements such as patient history, diagnosis and treatment.

5) Discussion: Discussion should focus on the case and pertinent literature, avoiding the lengthy literature review.

6) References: References follows the instruction in Original Articles.

(4) Review Article Review articles, focusing on a specific topic, usually solicited by the editorial committee. A review article should include Title page, Abstract and Key Words, Introduction, Text, Conclusion, References, Tables, and Figures.

(5) Editorials Editorials are invited by the editorial committee and should be commentaries on articles recently published in the JLA, and can be described in free style.

(6) Authors should complete the author checklist which is available in the JLA website and should submit it with the article.

(7) Subjects which are not described above will be decided by the Editorial Committee.

Publication charges and Author Reprints

(1) Authors may be requested to pay page charges in case of Original Articles or Case Reports based on the number of typeset pages, including illustrations, in the article. The actual cost of publishing in color or in a special format must be paid by the author before printing.

(2) Reprints may be purchased in a minimum of 50 copies by the request of the author. The estimate about reprints will be sent to the corresponding author with print proofs.

Copyright© by The Korean Society of Lipidology and Atherosclerosis. All rights reserved.
Room 1706, Taeyeong Desiang 320, Dongmak-ro, Mapo-gu, Seoul 04157, Korea
TEL : +82-2-3272-5330   FAX : +82-2-3272-5331   E-mail : ksla@lipid.or.kr      Powered by M2community